Treatment of transplanted tumor of lung adenocarcinoma A549 transfected by human somatostatin receptor subtype 2 (hsstr2) gene with 188Re-RC-160

Nuclear Medicine and Biology

Volumn 37, Issue 8, 2010, Pages 977-987

  Zhao, Rong ^a   Yang, Weidong ^a   Wang, Zhe ^a   Li, Guoquan ^a   Qin, Weiwei ^b   Wang, Jing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

188Re RC 160; A549; HSSTR2; PcDNA3 A549; PcDNA3 hSSTR2 A549; Targeting therapy

Indexed keywords

RHENIUM 188; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; VAPREOTIDE; VAPREOTIDE RE 188;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DISTRIBUTION; DRUG TARGETING; GENE EXPRESSION; GENE TRANSFER; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; RADIATION DOSE FRACTIONATION; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TUMOR NECROSIS;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CLONING, MOLECULAR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; RADIOISOTOPES; RECEPTORS, SOMATOSTATIN; RHENIUM; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSFECTION;

EID: 78049472392     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.05.007     Document Type: Article

References (44)

1. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003, 20:255-264.
2. Buchsbaum D.J. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Semin Nucl Med 2004, 34:32-46.
3. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor imaging. Semin Nucl Med 2002, 32:84-91.
4. l23I-Tyr']-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
5. Lamberts S.W.J., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 1991, 12:450-482.
6. Bakker W.H., Kreening E.P., Breeman W.A.P., et al. In vivo use of a radiolabeled somatostatin analog: dynamics, metabolism and binding to somatostatin receptor-positive tumors in man. J Nucl Med 1991, 32:1184-1189.
7. Krenning E.P., Bakker W.H., Kooij P.P.M., et al. Somatostatin receptor scintigraphy with In-111-DTPA-D-Phe-l-octreotide in man: metabolism, dosimetry and comparison with I-123-Tyr-3-octreotide. J Nucl Med 1992, 33:652-658.
8. Kvols L.K., Brown M.L., O'Connor M.K., et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 1993, 187:129-133.
9. Fjälling M., Andersson P., Forssell-Aronsson E., Gretarsdottir J., Johansson V., Tisell L.E., et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med 1996, 37:1519.
10. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000, 44:88.
11. 90Y-DOTATOC. J Nucl Med 2002, 43:610-616.
12. 3-octreotide. Eur J Nucl Med 2001, 28:426-434.
13. 3-octreotate in tumor-bearing rats. Nucl Med Biol 2001, 28:327-334.
14. 3]octreotate. Eur J Nucl Med 2003, 30:417-422.
15. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001, 92:628-633.
16. Schally A.V. Oncological applications of somatostatin analogues. Cancer Res 1988, 48:6977-6985.
17. 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 1996, 65:214-220.
18. 188Re-RC-160, a somatostatin analogue. Tumor Target 1996, 2:49.
19. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20:157-198.
20. Bousquet C., Puente E., Buscail L., Vaysse N., Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001, 47:30-39.
21. Gambhir S.S., Barrio J.R., Herschman H.R., et al. Assays for noninvasive imaging of reporter gene expression. Nucl Med Boil 1999, 26:481-490.
22. Woltering E.A. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 2003, 18:601-609.
23. Wang M., Caruano A.L., Lewis M.R., et al. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 2003, 63:6864-6869.
24. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
25. Munson P., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand binding systems. Anal Biochem 1980, 107:220-239.
26. Taniyama Y., Suzuki T., Mikami Y., Moriya T., Satomi S., Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 2005, 52:605-611.
27. 2 fragments. J Clin Invest 1989, 83:1449-1456.
28. Kwa H.B., Verhoeven A.H.M., Storm J., Vanzandwijk N., Mooi W.J., Hilkens J. Radioimmunotherapy of small cell lung cancer xenografts using iodine-131 -labelled anti-Ncam monoclonal antibody 123c3. Cancer Immunol Immunother 1995, 41:169-174.
29. Buchegger F., Rojas A., Delaloye A.B., et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res 1995, 55:83-89.
30. Meredith R.F., Khazaeli M.B., Liu T., et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992, 33:1648-1653.
31. DeNardo G.L., DeNardo S.J., O'Grady L.F., Levy N.B., Adams G.P., Mills S.L. Fractionated radioimmunotherapy of B-Cell malignancies with 131-Lym-l. Cancer Res 1990, 50(suppl):1014s-1016s.
32. Vallabhajosula S., Moyer B.R., James J.L., et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996, 37:1016-1022.
33. Gillespie J., Poston G.J., Schachter M., Guilloul P.J. Human pancreatic cancer cell lines do not express receptors for somatostatin. Br J Cancer 1992, 66:483-487.
34. Bernard B.F., Krenning E.P., Breeman W.A., et al. d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997, 38:1929-1933.
35. Behr T.M., Sharkey R.M., Sgouros G., et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997, 80:2591-2610.
36. Charland S., Boucher M.J., Houde M., Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001, 142:121-128.
37. Giannetti N., Enjalbert A., Krantic S. Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation. J Cell Biochem 2000, 78:666-673.
38. Lachowicz-Ochedalska A., Rebas E., Kunert-Radek J., Winczyk K., Pawlikowski M. Effects of somatostatin and its analogues on tyrosine kinase activity in rodent tumors. Biol Signals Recept 2000, 9:255-259.
39. Goldenberg D.M., DeLand F., Kim E., Bennett S., Primus F.J., van Nagell J.R., et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978, 298:1384-1386.
40. Yuan M., Wang J., Deng J., Wang Z., Yang W., Li G., et al. Combination therapy in A549 cells. Nucl Med Biol 2010, 37:317-326.
41. Takahashi M., Sato T., Sagawa T., et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002, 5:627-634.
42. Rogers B.E., Zinn K.R., Buchsbaum D.J. Gene transfer strategies for improving radiolabeled peptide imaging and therapy. Q J Nucl Med 2000, 44(3):208-223.
43. Wu Q., Moyana T., Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther 2001, 1(1):101-122.
44. Crystal R.G. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother Pharmacol 1999, 43(Suppl):S90-S99.